Hypofractionated radiotherapy in prostate cancer

The Lancet Oncology

Volumn 16, Issue 3, 2015, Pages 237-238

  Dearnaley, David P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CANADA; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; HYPOFRACTIONATED CANCER RADIOTHERAPY; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; INTERMEDIATE RISK PATIENT; INTERMETHOD COMPARISON; NEPHROTOXICITY; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED KINGDOM; GASTROINTESTINAL DISEASES; MALE; MALE UROGENITAL DISEASES; PROSTATIC NEOPLASMS; RADIATION INJURIES;

DOSE FRACTIONATION; GASTROINTESTINAL DISEASES; HUMANS; MALE; MALE UROGENITAL DISEASES; PROSTATIC NEOPLASMS; RADIATION INJURIES;

EID: 84925016225     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70021-5     Document Type: Note

References (12)

1. Mayles WP, Radiotherapy Development B Survey of the availability and use of advanced radiotherapy technology in the UK. Clin Oncol 2010, 22:636-642.
2. Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 2014, 15:464-473.
3. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13:43-54.
4. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2013, 85:686-692.
5. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 2009, 35:9-17.
6. Bentzen SM, Ritter MA The alpha/beta ratio for prostate cancer: what is it, really?. Radiother Oncol 2005, 76:1-3.
7. Fowler J, Chappell R, Ritter M Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 2001, 50:1021-1031.
8. Williams SG, Taylor JM, Liu N, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68:24-33.
9. Koontz BF, Bossi A, Cozzarini C, Wiegel T, D'Amico A A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol 2014, published online Aug 26. 10.1016/j.eururo.2014.08.009.
10. Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 2014, published online Feb 3. http://dx.doi.org/10.1016/S1470-2045(14)70482-6.
11. Barnett GC, De Meerleer G, Gulliford SL, Sydes MR, Elliott RM, Dearnaley DP The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clin Oncol 2011, 23:613-624.
12. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:980-988.